Alnylam is a biopharma developing novel therapeutics based on RNA Interference (RNAi). Their technology is often referred to as gene silencing.
RNAi is probably the biggest threat to a company that relies on peptide technology as with Phylogica.
Roche have announced, they will discontinue certain RNAi research.
In august Roche signed a $1.1 Bill deal with peptide company Aileron to use their 'Stapled Peptide' technology to piggy-back small molecule drugs into cells. This is the same space that PYC are working in with Roche.
To me it looks like Roche may be favoring cell penetrating peptides over RNA Interference.
Cheers ST
PYC Price at posting:
4.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)